With the advent of amphetamine-type drugs and pentamethylenetetrazol (Metrazol) (1) there has been a continued search for new antidepressants. The mono-amine oxidase inhibitors such as etryptamine (Monase) (2), phenelzine (Nardil) and nialamide (Niamide) gave fairly good results, though adverse side effects were noted in many cases. Just a few years ago another effective antidepressant was introduced-imipramine (Tofranil) (3, 4). However, side effects also were noted when this drug was given in relatively high doses to geriatric patients.Recently, various avenues of research have led to the development of a new type of antidepressant at the National Institutes of Health [Brodie's group (5)]. This new drug is desmethylimipramine (D.M.I.), which is a mono-ethyl analogue of imipramine. Desmethylimipramine is far more rapid in its action, and more potent than imipramine.Meduna, Abood and Biel (6) followed with work on anticholinergic agents. Considerable interest was aroused recently by studies of other secondary amines which led to the investigation of nortriptyline (7) (Fig. 1). This drug has a definite sedative, tranquilizing and antidepressant effect. Its discovery should open up new paths in the search for a drug of therapeutic value in the management of chronically ill and/or geriatric patients who suffer from depression, anxiety, apathy and irritability.Our investigation centered exclusively on the use of nortriptyline (Aventyl)' in the chronically ill and geriatric patient.
MATERIAL AND METHODSInitially, 65 patients suffering from various chronic illnesses associated with anxiety reactions, depression and other behavioral problems were selected for this study. Their ages ranged from 34 to 87 years, with an average of 59.8 years. There were 45 males and 20 females. The diagnoses were cerebral arteriosclerosis with or without chronic brain syndrome, generalized arteriosclerosis, multiple sclerosis and other spinal cord diseases, cerebrovascular accidents due to thrombosis or embolism, various cardiac diseases, chronic alcoholism and diabetes.
AKI is significantly less frequent and severe in iAAA patients after EVAR as compared to OAR. Furthermore OAR patients demonstrate a higher CKD rate. The identified risk factors may be prevented or modified as a bundle of measures especially in patients with pre-existing CKD to reduce AKI and its severity after iAAA repair.
The occurrence of a CSSS or CSVSS after coronary bypass surgery with retrograde flow in the ITA graft (as described in our four patients) is a rare, but potentially hazardous, situation. If the subclavian occlusion is not amenable to endovascular strategies, the extrathoracal approach by CSB or local TEA and patchplasty provides an excellent means with good midterm and long-term results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.